Overview

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

Status:
Completed
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.
Phase:
Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Azelaic acid